All In Biotech

Investigational drug · Phase 2

TRX-100

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Influenza.

Phase 2

Last checked: Nov 19, 2026Latest source record: Mar 31, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

4

Any phase or sponsor naming "TRX-100"

First trial start

2025

Dec 15, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "TRX-100", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Influenza

Approved drugs for the same conditions: Influenza · Infectious disease and vaccines

Largest trials

Live from ClinicalTrials.gov: studies naming "TRX-100" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 6 on PubMed

Also in development for Influenza

  • BioNTech SE · Influenza, COVID-19, COVID-19 (Coronavirus Disease 2019)

  • GP681Phase 32 trials

    Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Influenza, Human, Influenza

  • GP681 SimulantPhase 32 trials

    Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Influenza, Human, Influenza

  • BRC-201TG-1000, Pixavir MarboxilPhase 31 trial

    Boryung Biopharma Co., Ltd. · Influenza

  • mRNA-1018-H5Phase 31 trial

    Moderna · Influenza

  • Fluzone QudrivalentPhase 22 trials

    Sanofi · Healthy Volunteers, Influenza Immunization, Influenza

  • ApomivirFE-L-APO, drug substancePhase 21 trial

    Far East Bio-Tec Co., Ltd · Influenza

  • OVX836Phase 21 trial

    Osivax · Influenza

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.